Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of YHP2305 and YHR2404
NCT06613139Phase 1Completed
- Sponsor
- Yuhan
- Start
- Oct 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of YHP2305 (2 arms), sponsored by Yuhan. Primary endpoints: Area under the plasma drug concentration-time curve from time 0 to time t and Maximum plasma concentration. Started Oct 2024; status: completed.
02
Drugs
YHP2305
Beyond the preview
Go deeper on NCT06613139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06613139.